Telik Announces Appointment of Stephen K. Carter, M.D. to Scientific Advisory Board.Business Editors/Health and Medical Writers SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--Jan. 4, 2001 Telik, Inc. (Nasdaq: TELK) announced today the appointment of Stephen K. Carter, M.D., to its Scientific Advisory Board to assist in cancer drug development programs. Dr. Carter has served as Senior Vice President of Sugen Inc. since 1997. From 1995 to 1996 he served as Senior Vice-President of Research and Development at Boehringer Ingelheim Pharmaceuticals, Inc. From 1982 to 1995, Dr. Carter served as Senior Vice President of Worldwide Clinical Research and Development for Bristol-Myers Squibb Co. Dr. Carter received his M.D. from the New York Medical College New York Medical College is a center for graduate medical education located in Westchester County, a suburb half an hour north of New York City. This private university comprises the School of Medicine, which grants the M.D. . "Dr. Carter brings to the Telik drug development team extensive successful pharmaceutical industry experience in the development and approval of novel cancer drugs, including taxol and cis-platinum, which are currently two of the most important drugs for cancer treatment," said Michael M. Wick M.D., Ph.D., Telik's Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "His advice will greatly assist Telik as we prepare to initiate Phase II clinical testing of TLK TLK The Lion King TLK Thomas Liard Kennedy (Secondary School, Mississauga, Ontario, Canada) TLK Total Left Knee (replacement surgery) 286, a tumor activated cancer drug candidate intended for the treatment of tumors that have become resistant to standard therapies." "I am pleased to be joining the Telik team as an advisor," said Dr. Carter. "The safety and interesting biologic activity of TLK286 observed in the Phase I study conducted at the University of California, Los Angeles UCLA comprises the College of Letters and Science (the primary undergraduate college), seven professional schools, and five professional Health Science schools. Since 2001, UCLA has enrolled over 33,000 total students, and that number is steadily rising. and reported at the NCI/EORTC/AACR Symposium on New Drugs in Cancer Therapy in November 2000 provide a strong basis from which to launch a broad Phase II program. The Telik cancer drug pipeline offers an exciting opportunity to impact the treatment of cancer, a longstanding scientific interest of mine." Telik, Inc. of South San Francisco, California South San Francisco is a city in San Mateo County, California, United States, located on the San Francisco Peninsula in the San Francisco Bay Area. The population was 60,552 at the 2000 census. , is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases for which there is significant demand for new therapies. The company's most advanced drug development programs include: TLK286, a tumor activated drug candidate for the treatment of major cancers that are resistant to standard treatments; TLK199 for the treatment of depletion of infection-fighting white blood cells White blood cells A group of several cell types that occur in the bloodstream and are essential for a properly functioning immune system. Mentioned in: Abscess Incision & Drainage, Bone Marrow Transplantation, Complement Deficiencies that occurs as a toxic side effect of cancer therapy; and a family of orally active insulin receptor insulin receptor A heterodimeric membrane receptor composed of α and β chains, which has tyrosine kinase activity after binding insulin; IR deficiency is a rare cause of DM and may be due to a gene rearrangement, causing a deletion in the activators for Type 2 diabetes type 2 diabetes n. See diabetes mellitus. . Telik's product candidates were all discovered using its proprietary technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com. You should not rely on forward-looking statements contained in this press release including, but not limited to, statements regarding our ability to advance Telik's compounds to complete clinical development. Telik can give no assurance with regard to these statements. All of our product candidates are in the early stages of development, and the potential benefits of each product must still be proven. Additional information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release is set forth the caption "Risk Factors" in our prospectus filed with the Securities and Exchange Commission on August 11, 2000 and updated in our third quarter Form 10-Q Form 10-Q See 10-Q. filed on November 13, 2000. Telik assumes no obligation to update forward-looking information contained in this press release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion